Market Cap
$32.7B
DXCM
DEXCOM INC
$86.23 ▼ -0.07%
Prev close $86.29Market cap$32.7B
ConsensusStrong Buy
12-mo target$95.08 (+10.3%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)37 New Institutional Positions13 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on DXCM right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$19.6B
Inst. Activity
37 buys / 13 sells
Insider Activity
$0.00 buy / $12.0M sell
Insider Net $
-$12.0M
Social Sentiment
65° Warm
SEC Reports
11
Congressional
3 trades
Price chart 30d -3.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: DXCM — 77.1% short (0.9M / 1.2M)
Short: 897,253 | Exempt: 17 | TRF Vol: 1,163,002 | Short Ratio: 77.1% | Off-exchange volume (dark po
Sep 28, 2026 Insider
Stern Sadie sold 2,565 shares
EVP Chief People & Culture Off @ $86.15 ($221.0K)
Sep 15, 2026 Insider
AUGUSTINOS NICHOLAS sold 6,539 shares
Director @ $84.04 ($549.5K)
Sep 15, 2026 Insider
Sep 14, 2026 SEC Brown Michael Jon sold 1,700 shares
EVP Chief Legal Compliance Off @ $84.04 ($142.9K)
DexCom promoted CFO Jereme Sylvain to also serve as COO, effective September 14, 2026. His new offer letter provides an
8-K — Impact 2/10
A cluster of insider selling at Dexcom, totaling ~$236K, is dominated by an EVP's open-market sale of $227K. The CEO and
CLUSTER — Impact 2/10
Executive Chair Kevin Sayer sold ~$2.4M worth of DXCM shares in two open-market transactions on August 20, 2026, and EVP
CLUSTER — Impact 2/10
Jun 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP — DOUBLED
6,873,273 shares ($462.9M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 36 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Sep 18, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Sep 18, 2026 | TD Cowen | REITERATE | Buy | 56% |
| Aug 4, 2026 | Argus Research | MAINTAIN | Buy | 54% |
| Aug 3, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jul 31, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 31, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 31, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 31, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Jul 31, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 15 | 16 | 5 | 0 | 0 | 86% | |
| Aug 1, 2026 | 15 | 16 | 5 | 0 | 0 | 86% | |
| Jul 1, 2026 | 15 | 18 | 5 | 0 | 0 | 87% | |
| Jun 1, 2026 | 15 | 17 | 5 | 0 | 0 | 86% | |
| May 1, 2026 | 15 | 17 | 4 | 1 | 0 | 86% | |
| Apr 1, 2026 | 15 | 17 | 4 | 1 | 0 | 86% | |
| Mar 1, 2026 | 15 | 16 | 5 | 1 | 0 | 84% | |
| Feb 1, 2026 | 15 | 16 | 5 | 1 | 0 | 84% |
Price targets
Where 25 covering analysts think DXCM trades over the next 12 months.
$95.08 +10.3% upside Buy
Current$86.23 Low$79.00 Median$95.00 High$115.00 25 analysts
$79.00$115.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
65°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 10 neutral · avg impact 2.5/10.
NEUTRAL8-K2/10
DexCom promoted CFO Jereme Sylvain to also serve as COO, effective September 14, 2026. His new offer
Sep 14, 2026
NEUTRALCLUSTER2/10
A cluster of insider selling at Dexcom, totaling ~$236K, is dominated by an EVP's open-market sale o
Aug 28, 2026
NEUTRALCLUSTER2/10
Executive Chair Kevin Sayer sold ~$2.4M worth of DXCM shares in two open-market transactions on Augu
Aug 25, 2026
NEUTRALCLUSTER2/10
Two Dexcom insiders, including an EVP, sold a total of ~$246K in open-market sales over a week. Dire
Aug 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: DXCM — 77.1% short (0.9M / 1.2M)
Short: 897,253 | Exempt: 17 | TRF Vol: 1,163,002 | Short Ratio: 77.1% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: DXCM — 57.7% short (0.6M / 1.1M)
Short: 647,928 | Exempt: 100 | TRF Vol: 1,122,668 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: DXCM — 62.4% short (1.2M / 2.0M)
Short: 1,220,155 | Exempt: 4 | TRF Vol: 1,954,914 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: DXCM — 79.8% short (0.8M / 1.0M)
Short: 822,044 | Exempt: 0 | TRF Vol: 1,030,757 | Short Ratio: 79.8% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: DXCM — 71.8% short (0.8M / 1.1M)
Short: 809,892 | Exempt: 344 | TRF Vol: 1,127,204 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.67 | $0.62–$0.72 | 10.2% | +0.1% | 7↑ 9↓ | $1.3B | 21 |
| Next Q | $0.73 | $0.70–$0.77 | 8.0% | +0.1% | 5↑ 12↓ | $1.4B | 21 |
| Current FY | $2.66 | $2.45–$2.75 | 27.4% | +0.0% | 23↑ 0↓ | $5.2B | 25 |
| Next FY | $3.12 | $2.83–$3.29 | 17.2% | -0.1% | 18↑ 4↓ | $5.8B | 25 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.672 | — |
| 7d ago | $0.671 | +0.001 |
| 30d ago | $0.671 | +0.001 |
| 60d ago | $0.672 | -0.000 |
| 90d ago | $0.674 | -0.002 |
Institutional ownership
Which big funds own DXCM (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $19.6B total value (292,009,161 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 37 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 38,244,137 | $2.6B | 13.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 25,209,752 | $1.7B | 8.7% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 19,656,540 | $1.3B | 6.7% | — |
| STATE STREET CORP | 18,380,806 | $1.2B | 6.3% | — |
| Invesco Ltd. | 15,288,133 | $1.0B | 5.2% | — |
| BAILLIE GIFFORD & CO | 14,801,590 | $996.9M | 5.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 12,426,515 | $834.2M | 4.3% | — |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 11,261,876 | $758.5M | 3.9% | — |
| ALLIANCEBERNSTEIN L.P. | 11,693,409 | $734.3M | 3.7% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 8,527,471 | $574.3M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 2,545,103 | 6,873,273 | +170.1% | $462.9M |
| NORGES BANK | NEW | — | 6,868,090 | — | $462.6M |
| UBS Group AG | ADD | 4,349,959 | 6,065,779 | +39.4% | $408.5M |
| Castle Hook Partners LP | DOUBLED | 801,847 | 3,870,342 | +382.7% | $260.7M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | 1,934,452 | 3,560,621 | +84.1% | $240.9M |
| JPMORGAN CHASE & CO | TRIM | 5,999,470 | 3,325,095 | -44.6% | $232.7M |
| DEUTSCHE BANK AG\ | TRIM | 3,392,733 | 2,435,559 | -28.2% | $164.0M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 1,600,989 | 2,268,607 | +41.7% | $152.8M |
| NOMURA HOLDINGS INC | DOUBLED | 285,040 | 1,709,370 | +499.7% | $115.1M |
| CI INVESTMENTS INC. | ADD | 872,578 | 1,287,663 | +47.6% | $86.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$12.0M — $0.00 bought, $12.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Stern Sadie | EVP Chief People & Culture Off | SELL | 2,565 | $86.15 | $221.0K |
| Sep 15, 2026 | AUGUSTINOS NICHOLAS | Director | SELL | 6,539 | $84.04 | $549.5K |
| Sep 15, 2026 | Brown Michael Jon | EVP Chief Legal Compliance Off | SELL | 1,700 | $84.04 | $142.9K |
| Sep 14, 2026 | AUGUSTINOS NICHOLAS | Director | SELL | 1,550 | $84.02 | $130.2K |
| Sep 10, 2026 | Boehnlein Glenn S | Director | AWARD | 5,841 | — | — |
| Sep 10, 2026 | Sylvain Jereme M | EVP, Chief Financal Officer | SELL | 3,638 | $83.27 | $302.9K |
| Aug 27, 2026 | Stern Sadie | EVP Chief People & Culture Off | SELL | 2,565 | $88.37 | $226.7K |
| Aug 22, 2026 | Sylvain Jereme M | EVP, Chief Financal Officer | TAX W/H | 1,451 | $92.34 | $134.0K |
| Aug 22, 2026 | Stern Sadie | EVP Chief People & Culture Off | TAX W/H | 1,451 | $92.34 | $134.0K |
| Aug 22, 2026 | Brown Michael Jon | EVP Chief Legal Compliance Off | TAX W/H | 1,451 | $92.34 | $134.0K |
Congressional trades
DXCM trades disclosed by members of Congress, with disclosure delay.
3 members · 2 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | DexCom Inc | May 13, 2026(31d) |
| Feb 4, 2026 | Michael McCaul | R | HOUSE | SELL | $1,001 - $15,000 | DexCom Inc | Mar 12, 2026(37d) |
| Jan 26, 2026 | John Boozman | R | SENATE | BUY | $1,001 - $15,000 | DexCom Inc | Feb 15, 2026(21d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DXCM.
Shares short
17,263,625
Settlement Sep 15, 2026
Change vs prior
-2.1%
Semi-monthly cycle
Days to cover
5.0
At avg daily volume
Of shares outstanding
≈4.6%
Estimate — not % of float
All DXCM filing & press-release reports (11)
- 8-K reportSep 14, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportJul 21, 2026
- CLUSTER reportJun 17, 2026
- CLUSTER reportMay 27, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 19, 2026
- DEFA14A reportApr 15, 2026
- INST-CLUSTER reportFeb 28, 2026